Gómez-Garre Dulcenombre, Herraíz Marta, González-Rubio Ma Luisa, Bernal Rosa, Aragoncillo Paloma, Carbonell Amparo, Rufilanchas Juan José, Fernández-Cruz Arturo
Vascular Biology and Atherosclerosis Research Laboratory, Area de Prevención Cardiovascular y Rehabilitación Cardíaca, Instituto Cardiovascular, Spain.
Eur J Heart Fail. 2006 Mar;8(2):154-61. doi: 10.1016/j.ejheart.2005.06.002. Epub 2005 Sep 26.
Peroxisome proliferator-activated receptors (PPARs), key transcriptional regulators of lipid and energy metabolism in cardiomyocytes, have recently been proposed to modulate cardiovascular pathophysiological responses in experimental models. However, there is little information about the functional activity of PPARs in human heart failure.
To investigate PPAR-alpha and -gamma expression and activity, and the association with ET-1 production and fibrosis, in cardiac biopsies from patients with end-stage heart failure due to ischemic cardiomyopathy (ICM) in comparison and from non-failing donor hearts. All samples were obtained during cardiac transplantation.
Morphological analysis (by Masson trichrome and image analysis) did not detect fibrosis in the left atrium from non-failing donors (NFLA) or from ICM patients (FLA). However, left ventricles from failing hearts (FLV) contained a greater number of fibrotic areas (NFLA: 3.21+/-1.15, FLA: 1.63+/-0.83, FLV: 14.5+/-3.45%; n = 9, P<0.05). By RT-PCR, preproET-1 expression was similar in the non-failing and failing atrium but was significantly higher in the ventricles from failing hearts (NFLA: 1.00+/-0.06, FLA: 1.08+/-0.11, FLV: 1.74+/-0.19; n = 9, P<0.05). PPAR-alpha and PPAP-gamma mRNA (by RT-PCR) and protein (by Western blot) levels were higher in the ventricles from failing hearts compared with the atrium from failing and non-failing hearts. Electrophoretic mobility shift assays showed that PPAR-alpha and PPAP-gamma were not activated in the ventricles (NFLA: 1.00+/-0.11, FLA: 1.89+/-0.24, FLV: 0.95+/-0.07; n = 9, P<0.05).
These data suggest that PPAR-alpha and PPAP-gamma are selectively activated in the atria from ICM patients and might be functionally important in the maintenance of atrial morphology.
过氧化物酶体增殖物激活受体(PPARs)是心肌细胞脂质和能量代谢的关键转录调节因子,最近有研究提出其可调节实验模型中的心血管病理生理反应。然而,关于PPARs在人类心力衰竭中的功能活性的信息却很少。
比较缺血性心肌病(ICM)所致终末期心力衰竭患者与非衰竭供体心脏的心脏活检组织中PPAR-α和 -γ的表达及活性,以及它们与ET-1产生和纤维化的关系。所有样本均在心脏移植过程中获取。
形态学分析(通过Masson三色染色和图像分析)未检测到非衰竭供体左心房(NFLA)或ICM患者左心房(FLA)有纤维化。然而,衰竭心脏的左心室(FLV)含有更多的纤维化区域(NFLA:3.21±1.15,FLA:1.63±0.83,FLV:14.5±3.45%;n = 9,P<0.05)。通过逆转录聚合酶链反应(RT-PCR)检测,前原ET-1在非衰竭和衰竭心房中的表达相似,但在衰竭心脏的心室中显著更高(NFLA:1.00±0.06,FLA:1.08±0.11,FLV:1.74±0.19;n = 9,P<0.05)。与衰竭和非衰竭心脏的心房相比,衰竭心脏心室中的PPAR-α和PPAP-γ信使核糖核酸(通过RT-PCR)及蛋白质(通过蛋白质免疫印迹法)水平更高。电泳迁移率变动分析表明,PPAR-α和PPAP-γ在心室中未被激活(NFLA:1.00±0.11,FLA:1.89±0.24,FLV:0.95±0.07;n = 9,P<0.05)。
这些数据表明,PPAR-α和PPAP-γ在ICM患者的心房中被选择性激活,可能在维持心房形态方面具有重要功能。